Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9223901 | 0.88 | DHODH (0.42) | DHODHPIK3CGNPC1METBACE1 | |
| SCHEMBL20061458 | 0.78 | PDE10A (0.57) | PIK3CGNPC1 | |
| SCHEMBL20061318 | 0.78 | PDE10A (0.57) | PIK3CGNPC1 | |
| SCHEMBL8669576 | 0.77 | ADORA2A (0.38) | DHODHPIK3CGADORA2A | |
| SCHEMBL28261532 | 0.76 | PDE10A (0.59) | DHODHNPC1BACE1 | |
| SCHEMBL6004191 | 0.76 | DHODH (0.41) | DHODHPIK3CGNPC1ADORA2A | |
| SCHEMBL10080210 | 0.75 | PIK3CG (0.37) | DHODHPIK3CGADORA2AMETMAPK14 | |
| SCHEMBL15302654 | 0.75 | PIK3CG (0.37) | DHODHPIK3CGADORA2AMETMAPK14 | |
| SCHEMBL9953062 | 0.75 | PIK3CG (0.37) | DHODHPIK3CGADORA2AMETMAPK14 | |
| SCHEMBL361776 | 0.74 | AKT1 (0.49) | DHODHNPC1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| WO-2012087784-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087784-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | DHODH 2700/4885PIK3CG 59/4885NPC1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.